Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/bjsports-2023-107341 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intra-Mesopore Immunoassay Based on Core-Shell Structured Magnetic Hierarchically Porous ZIFs.
ACS Sens
January 2025
Key Laboratory for Ultrafine Materials of Ministry of Education, School of Materials Science and Engineering, East China University of Science and Technology, Shanghai 200237, China.
It is crucial yet challenging to sensitively quantify low-abundance biomarkers in blood for early screening and diagnosis of various diseases. Herein, an analytical model of intra-mesopore immunoassay (IMIA) was proposed, which was competent to examine various biomarkers at the femtomolar level. The success is rooted in the design of an innovative superparamagnetic core-shell structure with FeO nanoparticles (NPs) at the core and hierarchically porous zeolitic imidazolate frameworks as a shell (FeO@HPZIF-8), achieved through a soft-template directed self-assembly coupled with confinement growth mechanism.
View Article and Find Full Text PDFEarly Use of Liraglutide for the Treatment of Acute COVID-19 Infection: An Open-Label Single-Center Phase II Safety Study with Biomarker Profiling.
Infect Dis Rep
January 2025
Royal Brompton Hospital, Part of GSTT NHS Foundation Trust, London SW3 6NP, UK.
Background: Glucagon-like peptide-1 (GLP-1) agonists are an existing treatment option for patients with insulin-resistant states, which elicit further pleiotropic effects related to immune cell recruitment and vascular inflammation. GLP-1 agonists downregulate the cluster of differentiation 147 (CD147) receptor, one of several receptors for the SARS-CoV-2 spike protein that mediate viral infection of host cells.
Methods: We conducted an open-label prospective safety and tolerability study including biomarker responses of the GLP-1 agonist Liraglutide, administered for 5 days as an add-on therapy to the standard of care within 48 h of presentation in a cohort of 13 patients hospitalized with COVID-19 pneumonia.
Cardiac myosin binding protein C correlate with cardiac troponin I during an exercise training program in patients with HFrEF.
ESC Heart Fail
January 2025
Department of Cardiology, Stavanger University Hospital, Stavanger, Norway.
Background: Cardiac myosin binding protein C (cMyC) is an emerging new biomarker of myocardial injury rising earlier and cleared faster than cardiac troponins. It has discriminatory power similar to high-sensitive troponins in diagnosing myocardial infarction in patients presenting with chest pain. It is also associated with outcome in patients with acute heart failure.
View Article and Find Full Text PDFImpact of Acute Myocardial Injury on Short- and Long-Term Outcomes in Patients With Primary Intracerebral Hemorrhage.
J Am Heart Assoc
January 2025
Department of Neurology The Second Affiliated Hospital, School of Medicine, Zhejiang University Hangzhou Zhejiang China.
Background: Myocardial injury is common after brain injury; however, few studies have reported serial cardiac troponin (cTn) measurements to distinguish whether the myocardial injury is acute or chronic. The fourth Universal Definition of Myocardial Infarction introduced for the first time the criteria for acute myocardial injury (AMI). We aimed to investigate the prevalence and prognostic implications of AMI in primary intracerebral hemorrhage.
View Article and Find Full Text PDFPerformance of computerized self-reported medical history taking and HEAR score for safe early rule-out of cardiac events in acute chest pain patients: the CLEOS-CPDS prospective cohort study.
Eur Heart J Digit Health
January 2025
Division of Cardiovascular Medicine, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, SE-182 88 Stockholm, Sweden.
Aims: A simplified version of the history, electrocardiogram, age, risk factors, troponin (HEART) score, excluding troponin, has been proposed to rule-out major adverse cardiac events (MACEs). Computerized history taking (CHT) provides a systematic and automated method to obtain information necessary to calculate the HEAR score. We aimed to evaluate the efficacy and diagnostic accuracy of CHT in calculating the HEAR score for predicting MACE.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!